The worldwide demand for erythropoietin drugs also referred as hematopoietic drugs is expected to remain strong in the forthcoming years. Market Research Future (MRFR) reports that the global erythropoietin drug market will post a above-average CAGR between 2017 and 2023. The outlook remains positive for the global erythropoietin drug market for the medium terms.
Erythropoietin drug are used for treating a wide range of disorders, which include AIDS, chronic renal diseases, anaemia, cancer, among others. Increased prevalence of such diseases is boosting the sales of erythropoietin. Over the years, tremendous investment has been made in research & development programs focused on drug discovery, which has also influenced the market growth to certain extent. Several new erythropoietin drug combinations have come up in recent years. Introduction of new drug combinations is allowing to drug makers to cater to wider pool of patients.
Receive FREE Sample Here: https://www.marketresearchfuture.com/sample_request/1360
Rising awareness among patients and increased focus on improving healthcare services in the developing countries is likely to open new growth avenues for market players in near future. On the other hand, most of the erythropoietin drug available are highly priced, which makes their penetration in price sensitive markets difficult. This is viewed as a major market constraint. Patient expiry and introduction of generic variants may provide an impetus to drug penetration. Focus is also shifting on developing alternative drugs formulations.
Amgen (US), Teva Pharmaceutical Industries Ltd. (Israel), Emcure Pharmaceuticals (India), Hospira (US), LG Life Sciences Ltd. (Korea), Kyowa Hakko Kirin, Boehringer Ingelheim (US), Intas Pharmaceuticals (India), Hoffmann-La Roche (Switzerland), Johnson & Johnson (US), Celltrion, Inc. (South Korea), 3SBio, Biocon (India), BIOSIDUS (Argentina), and Dahua Pharmaceutical (China).
- Reportedly, well before any other country, China approves a new anaemia drug “Roxadustat” from FibroGen and AstraZeneca. Roxadustat supports a novel oral anaemia treatment known as hypoxia-inducible factor prolyl hydroxylase inhibitor. The drug is viewed as a convenient alternative to erythropoietin or EPO.
- AstraZeneca has recently partnered with UK-based artificial intelligence specialist BenevolentAI. The partnership will allow AstraZeneca to leverage machine learning and AI for drug discovery projects focusing on idiopathic pulmonary fibrosis (IPF) and chronic kidney disease (CKD).
MRFR’s report includes a thorough segmental analysis of the global erythropoietin drug market based on product type, application and end user.
On the basis of product type, the market has been segmented into second generation formulation, first generation formulation and biosimilars. On the basis of application, the market has been segmented into renal diseases, HIV, oncology and other. On the basis of end user, the market has been segmented into pharmacy and hospital.
Access Report Details @ https://www.marketresearchfuture.com/reports/erythropoietin-drug-market-1360
Global Erythropoietin Drug Market: Regional Segmentation
On the basis of region, the market has been segmented into North America, South America, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA). North America represents the largest market for Erythropoietin. This growth can be partly attributed to rising cancer prevalence and increased incidence of renal diseases in the U.S. and Canada. Other factors that favour the market growth in the region include widespread accessibility of cutting-edge medical services and strong government support. North America is followed by Europe and APAC respectively.
The market is likely to witness towering gains in APAC in particular. In addition, the APAC erythropoietin drug market is projected to exhibit the fastest growth during the forecast period. Increased penetration of healthcare services and expanding patient population in countries such as China and India. Moreover, increased government effort to improve healthcare in these countries is creating further opportunities. LatAm and the MEA regions hold relatively lower share of the global erythropoietin drug market.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312
Email: [email protected]